Omnicell, Inc.: A Pharmaceutical Technology Leader
Omnicell, Inc. (OMCL) holds a Zacks Rank #1, with its yearly earnings estimate surging by 16.7% in the past 60 days. The company’s stock saw an impressive 56.3% rise in the last three months, outperforming the S&P 500’s 2.3% increase. With a Momentum Score of B, Omnicell is a strong contender in the pharmaceutical technology sector.
ServisFirst Bancshares, Inc.: A Strong Player in Banking
ServisFirst Bancshares, Inc. (SFBS) also boasts a Zacks Rank #1, with its current year earnings estimate increasing by 1.8% over the last 60 days. The company’s shares surged by 28.5% in the past three months, surpassing the S&P 500’s growth of 2.3%. ServisFirst Bancshares has a Momentum Score of A, highlighting its potential in the banking industry.
Zacks’ Top Pick for Doubling Your Investment
Zacks’ Research Chief has identified a stock with the potential to double in the coming months. This innovative financial firm, already serving over 50 million customers, offers cutting-edge solutions and promising prospects for investors. While not all recommendations yield positive returns, this stock could outshine previous picks like Nano-X Imaging, which soared by +129.6% in just over 9 months.
Explore the full list of top-ranked stocks here.
Learn more about the Momentum score and how it is calculated here.
Identify Our Top Stock And 4 Runners Up for Free
Omnicell, Inc. (OMCL) : Access Free Stock Analysis Report
ServisFirst Bancshares, Inc. (SFBS) : Access Free Stock Analysis Report
Read the full article on Zacks.com here.
Note: The opinions expressed are those of the author and do not necessarily reflect the views of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
